919 Stock Overview
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products and medical devices in China.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Jinling Pharmaceutical Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.96 |
| 52 Week High | CN¥10.13 |
| 52 Week Low | CN¥5.38 |
| Beta | 0.47 |
| 1 Month Change | 0.29% |
| 3 Month Change | 6.59% |
| 1 Year Change | -9.96% |
| 3 Year Change | -18.50% |
| 5 Year Change | -21.80% |
| Change since IPO | -16.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| 919 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 6.9% | 5.7% | 4.2% |
| 1Y | -10.0% | -11.0% | -13.2% |
Return vs Industry: 000919 exceeded the CN Pharmaceuticals industry which returned -11% over the past year.
Return vs Market: 000919 exceeded the CN Market which returned -13.2% over the past year.
Price Volatility
| 919 volatility | |
|---|---|
| 919 Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 7.7% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 000919 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000919's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 4,880 | n/a | jlyy1999.com |
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products and medical devices in China. The company provides Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, polyarteritis, acute arterial embolism of extremities, diabetic gangrene, intravenous thrombus, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; lentinan injection for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of wound hemostasis. It also offers medical and health care services.
Jinling Pharmaceutical Company Limited Fundamentals Summary
| 919 fundamental statistics | |
|---|---|
| Market cap | CN¥4.38b |
| Earnings (TTM) | CN¥99.61m |
| Revenue (TTM) | CN¥2.82b |
44.0x
P/E Ratio1.6x
P/S RatioIs 919 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 919 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.82b |
| Cost of Revenue | CN¥2.22b |
| Gross Profit | CN¥606.78m |
| Other Expenses | CN¥507.17m |
| Earnings | CN¥99.61m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.16 |
| Gross Margin | 21.49% |
| Net Profit Margin | 3.53% |
| Debt/Equity Ratio | 0.007% |
How did 919 perform over the long term?
See historical performance and comparison